Amy Deipolyi

Dr. Amy Deipolyi


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2019 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
Jingjie HuJingjie Hu
Jingjie Hu
HAHassan Albadawi
Hassan Albadawi
BCBrian W. Chong
Brian W. Chong
ADAmy Deipolyi
Amy Deipolyi
RSRahul A. Sheth
Rahul A. Sheth
RORahmi Oklu
Rahmi Oklu

4 September 2007 in Neurology
Verified
Journal Article
Closed access
PDF file
ADAmy Deipolyi
Amy Deipolyi
KRK. P. Rankin
K. P. Rankin
LML. Mucke
L. Mucke
BMB. L. Miller
B. L. Miller
MGM. L. Gorno-Tempini
M. L. Gorno-Tempini
Background: The mechanisms underlying navigation impairments in Alzheimer disease (AD) are unknown. We characterized navigation in AD and mild cognitive impairment (MCI) to test the hypothesis that navigation disability reflects selective impairments in spatial cognition and relates to atrophy of specific brain regions.

1 May 2014 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
DPDarci Phillips
Darci Phillips
ADAmy Deipolyi
Amy Deipolyi
RHRichard Hesketh
Richard Hesketh
MMMehran Midia
Mehran Midia
RORahmi Oklu
Rahmi Oklu

1 September 2005 in NeuroImage
Verified
Journal Article
Closed access
ADAmy Deipolyi
Amy Deipolyi
PMPratik Mukherjee
Pratik Mukherjee
KGKanwar Gill
Kanwar Gill
RHRoland G. Henry
Roland G. Henry
SPSavannah C. Partridge
Savannah C. Partridge
ABA. James Barkovich
A. James Barkovich

1 December 2017 in Cardiovascular Diagnosis and Therapy
Verified
Journal Article
Closed access
PDF file
CCChristopher Czaplicki
Christopher Czaplicki
HAHassan Albadawi
Hassan Albadawi
SPSasan Partovi
Sasan Partovi
RGRipal T. Gandhi
Ripal T. Gandhi
KQKeith Quencer
Keith Quencer
RORahmi Oklu
Rahmi Oklu
Venous thrombosis (VT) is a common yet complex clinical condition that has shown minimal alteration in clinical management for decades. It is well known that thrombus evolves structurally over time, with complex changes resulting from the interplay between coagulation factors, cytokines, leukocytes and a myriad of other factors. Our current treatment options are most effective in the acute thrombus, which is composed predominantly of a loose mesh of fibrin and red blood cells (RBCs), making current anticoagulation therapies and thrombolytics quite effective in treatment. Later stages of thrombus are more cellular containing leukocytes, and develop a fibrotic collagenous framework that is more resistant to our current treatments. Understanding the biology of an evolving thrombus will allow us to tailor our treatment and optimize outcomes, as well as focus on novel therapies for the treatment of chronic thrombus. Given the morbidity and mortality of both post thrombotic syndrome (PTS) in patients with deep VT, as well as chronic thromboembolic pulmonary hypertension (CTEPH) in patients with pulmonary embolism (PE), new and innovative therapies must continue to be explored to help prevent these potentially devastating conditions.

1 March 2013 in Vasa
Verified
Journal Article
Closed access
NBNicholas F. Brazeau
Nicholas F. Brazeau
HHHarlan B. Harvey
Harlan B. Harvey
EPErique G. Pinto
Erique G. Pinto
ADAmy Deipolyi
Amy Deipolyi
RHRichard Hesketh
Richard Hesketh
RORahmi Oklu
Rahmi Oklu
For over fifty years, the pathogenesis of May-Thurner syndrome (MTS) has been associated with chronic left common iliac vein compression resulting in the formation of intraluminal, permanent obstructive lesions. However, despite this association, the mechanism by which compression produces these lesions is unknown. Diagnostic accuracy of MTS is critical since it often afflicts young patients requiring endovascular management. This review will focus on the historical, embryological and evolutionary description of MTS and examine its development, diagnosis, clinical management and potential diagnostic errors.